



Anika to Present at the Singular Research Summer Solstice Conference on July 13, 2017

BEDFORD, Mass.--(BUSINESS WIRE)-- **Anika Therapeutics, Inc.** (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary **hyaluronic acid ("HA") technology**, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the Singular Research Summer Solstice Conference on Thursday, July 13, 2017 at 9:00 am ET. The conference is being held at the Metro Meeting Centers in Boston, MA.

A live audio webcast of the presentation may be accessed via the "**Investor Relations**" section of Anika's website at www.anikatherapeutics.com. An audio archive of the presentation also will be available on the website.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary **hyaluronic acid (HA) technology**. Anika's orthopedic medicine portfolio includes **ORTHOVISC®**, **MONOVISC®**, and **CINGAL®**, which alleviate pain and restore joint function by replenishing depleted HA, and **HYALOFAST®**, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170706005641/en/>

For Investor Inquiries:

Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer

or

For Media Inquiries:

Pure Communications, Inc.
Sonal Vasudev, 917-523-1418
sonal@purecommunicationsinc.com

Source: Anika Therapeutics, Inc.

News Provided by Acquire Media
